NEWSROOM

GILD

Immutep Advances Towards Phase III Trial for Lung Cancer Treatment with Positive Regulatory Feedback

Immutep Advances Towards Phase III Trial for Lung Cancer Treatment with Positive Regulatory Feedback

New York, December 27, 2023 - Immutep Limited (ASX: IMM; NASDAQ: IMMP), a trailblazing clinical-stage biotechnology company, has announced encouraging news from the Paul-Ehrlich-Institut (PEI), part of the Committee for Medicinal Products for Human Use (CHMP). This announcement marks a significant step forward in the company’s development of novel LAG-3 immunotherapies for cancer and autoimmune diseases. https://prismmarketview.com/companies/immutep-limited/#news Marc Voigt, CEO of Immutep...

read more
HOOKIPA Stock Jumps Following $21.25M Gilead Equity Investment

HOOKIPA Stock Jumps Following $21.25M Gilead Equity Investment

New York, December 22, 2023 - Gilead Sciences (Nasdaq: GILD) has purchased 15 million shares of immunotherapeutics company, HOOKIPA Pharma’s (Nasdaq: HOOK), common stock for approximately $21.25 million, at a price of $1.4167 per share. Under the agreement, HOOKIPA is responsible for advancing its HIV program through the completion of a Phase 1b clinical trial. The company’s shares rose 52.65% on Thursday and 80.51% premarket on Friday. https://prismmarketview.com/companies/hookipa-pharma-inc/...

read more

Categories

Loading
Translate »